PB-102-F01: PRX-102 for ERT in patients with Fabry disease

• Research type

  Research Study

• Full title

  A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients

• IRAS ID

  121141

• Contact name

  Derralynn Hughes

• Contact email

  rmgvdah@ucl.ac.uk

• Sponsor organisation

  Protalix Ltd.

• Eudract number

  2012-004786-40

• Clinicaltrials.gov Identifier

  NCT01678898

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  13/LO/0334

• Date of REC Opinion

  10 May 2013

• REC opinion

  Further Information Favourable Opinion